Imunon (IMNN) Projected to Release Quarterly Earnings on Tuesday

Imunon (NASDAQ:IMNN) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.8675) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 11:00 AM ET.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.38. On average, analysts expect Imunon to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Imunon Stock Performance

Shares of IMNN stock opened at $1.59 on Friday. Imunon has a 52-week low of $1.47 and a 52-week high of $8.19. The stock has a market cap of $6.68 million, a price-to-earnings ratio of -0.31 and a beta of 1.96. The firm has a fifty day moving average of $1.90 and a 200-day moving average of $2.66.

Analysts Set New Price Targets

A number of research firms recently weighed in on IMNN. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a research note on Friday, July 17th. Maxim Group set a $10.00 price target on shares of Imunon and gave the stock a “buy” rating in a research report on Friday, April 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Imunon presently has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Imunon

A hedge fund recently bought a new position in Imunon stock. Armistice Capital LLC acquired a new stake in Imunon, Inc. (NASDAQ:IMNN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon as of its most recent filing with the SEC. 4.47% of the stock is owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.